Complementary and alternative treatments of attention deficit hyperactivity disorder

KILINÇASLAN, Ayşe; TUTKUNKARDAŞ, Mustafa Deniz; MUKADDES, Nahit Motavallı

Complementary and alternative treatments of attention deficit hyperactivity disorder

Ayşe KILINÇASLAN, (İstanbul Üniversitesi, İstanbul Tıp Fakültesi, Çocuk Ruh Sağlığı ve Hastalıkları Anabilim Dalı, İstanbul, Türkiye)

Mustafa Deniz TUTKUNKARDAŞ, (İstanbul Üniversitesi, İstanbul Tıp Fakültesi, Çocuk Ruh Sağlığı ve Hastalıkları Anabilim Dalı, İstanbul, Türkiye)

Nahit Motavallı MUKADDES (İstanbul Üniversitesi, İstanbul Tıp Fakültesi, Çocuk Ruh Sağlığı ve Hastalıkları Anabilim Dalı, İstanbul, Türkiye)

Nöropsikiyatri Arşivi

4 1

Yıl: 2011 Cilt: 48 Sayı: 2 Sayfa Aralığı: 94 - 102 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Complementary and alternative treatments of attention deficit hyperactivity disorder

Öz:

Dikkat eksikliği hiperaktivite bozukluğu (DEHB) çocukların yaklaşık %5-10 kadarını etkileyen en yaygın psikiyatrik durumlardan biridir. Kronik seyirli bir bozukluktur ve sıklıkla erişkinliğe kadar sürer. DEHB tedavisinde kullanımı onaylanmış farmakolojik ajanlar psikostimülanları ve atomoksetini içerir. Ancak ilaç dışı tedavi arayışları ve tamamlayıcı ve alternatif tıp kullanımı artış göstermektedir.Burada, DEHB'de en sık kullanılan tamamlayıcı ve alternatif tedaviler gözden geçirilecektir.

Anahtar Kelime:

Konular: Nörolojik Bilimler Psikiyatri

Dikkat eksikliği hiperaktivite bozukluğunda tamamlayıcı ve alternatif tedaviler

Öz:

Attention deficit hyperactivity disorder (ADHD) is one of the most common psychiatric conditions estimated to affect 5-10% of the children. It is a chronic condition and frequently persists into adulthood. Approved pharmacological agents for the treatment of ADHD include psychostimulants and atomoxetine. However,non-pharmacological treatment seeking and the use of complementary and alternative medicine are on the rise. Here, the most common complementary and alternative treatments of ADHD will be reviewed.

Anahtar Kelime:

Konular: Nörolojik Bilimler Psikiyatri

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık

1.American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders Text Revision. 4th ed. Washington DC: American Psychiatric Association; 2000.
2. Pliszka S, AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007; 46:894-921.
3. Greenhill L, Beyer D, Finkleson J et al. Guidelines and algorithms for the use of methylphenidate in children with Attention-Deficit/ Hyperactivity Disorder. J Atten Disord 2002; 6(Suppl 1):89-100.
4. McCracken J, Biederman J, Greenhill L et al. Analog classroom assessment of a once-daily mixed amphetamine formulation, SLI381 (Adderall XR), in children with ADHD. J Am Acad Child Adolesc Psychiatry 2003; 42:673-83.
5. Wigal S, McGough J, McCracken J et al. A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with attention deficit/hyperactivity disorder. J Atten Disord 2005; 9:275-89.
6. Wolraich M, Greenhill L, Pelham W et al. Randomized, controlled trial of oros methylphenidate once a day in children with attentiondeficit/ hyperactivity disorder. Pediatrics 2001; 108:883-92.
7. Michelson D, Faries D, Wernicke J et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 2001; 108:E83.
8. Michelson D, Adler L, Spencer T et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry 2003; 53:112-20.
9. Kutcher S, Aman M, Brooks S et al. International consensus statement on attention-deficit/hyperactivity disorder (ADHD) and disruptive behaviour disorders (DBDs): clinical implications and treatment practice suggestions. Eur Neuropsychopharmacol 2004;14:11-28.
10. No authors listed. Guanfacine extended-release (intuniv) for ADHD. Med Lett Drugs Ther 2010; 52:82-3.
11. Biederman J, Melmed RD, Patel A et al. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics 2008; 121:e73-e84.
12. Sallee FR, Lyne A, Wigal T et al. Long-term safety and efficacy of guanfacine extended release in children and adolescents with attentiondeficit/ hyperactivity disorder. J Child Adolesc Psychopharmacol 2009; 19:215-26.
13. Pelham WJ, Wheeler T, Chronis A. Empirically supported psychosocial treatments for attention deficit hyperactivity disorder. J Clin Child Psychol 1998; 27:190-205.
14. Spencer TJ. Antidepressant and specific norepinephrine reuptake inhibitor treatments. In: Barkley RD, editor. Attention-deficit hyperactivity disorder. 3rd edition. New York: Guilford Press; 2006. p. 648-57.
15. Gross-Tsur V, Lahad A, Shalev R. Use of complementary medicine in children with attention deficit hyperactivity disorder and epilepsy. Pediatr Neurol 2003; 29:53-5.
16. Madsen H, Andersen S, Nielsen R et al. Use of complementary/alternative medicine among paediatric patients. Eur J Pediatr 2003;162:334-41.
17. Sinha D, Efron D. Complementary and alternative medicine use in children with attention deficit hyperactivity disorder. J Paediatr Child Health 2005; 41:23-6.
18. Karpouzis F, Bonello R, Pollard H. Chiropractic care for paediatric and adolescent Attention-Deficit/Hyperactivity Disorder: A systematic review. Chiropr Osteopat 2010;18.
19. Loo S, Barkley R. Clinical utility of EEG in attention deficit hyperactivity disorder. Appl Neuropsychol 2005; 12:64-76.
20. Chabot R, Serfontein G. Quantitative electroencephalographic profiles of children with attention deficit disorder. Biol Psychiatry 1996; 40:951-63.
21. Clarke A, Barry R, McCarthy R et al. Excess beta activity in children with attention-deficit/hyperactivity disorder: an atypical electrophysiological group. Psychiatry Res 2001; 103:205-18.
22. Gevensleben H, Holl B, Albrecht B et al. Is neurofeedback an efficacious treatment for ADHD? A randomised controlled clinical trial. J Child Psychol Psychiatry 2009; 50:780-9.
23. Lubar J, Shouse M. EEG and behavioral changes in a hyperkinetic child concurrent with training of the sensorimotor rhythm (SMR): a preliminary report. Biofeedback Self Regul 1976;1:293-306.
24. Omizo M, Michael W. Biofeedback-induced relaxation training and impulsivity, attention to task, and locus of control among hyperactive boys. J Learn Disabil 1982; 15:414-6.
25. Linden M, Habib T, Radojevic V. A controlled study of the effects of EEG biofeedback on cognition and behavior of children with attention deficit disorder and learning disabilities. Biofeedback Self Regul 1996; 21(1):35-49. Erratum in: 1996; 21:297.
26. Rossiter T, Vaque TL. A comparison of EEG biofeedback and psychostimulants in treating attention deficit/hyperactivity disorders. J Neurotherapy 1995; 1:48-59.
27. Monastra V, Monastra D, George S. The effects of stimulant therapy, EEG biofeedback, and parenting style on the primary symptoms of attention-deficit/hyperactivity disorder. Appl Psychophysiol Biofeedback 2002; 27:231-49.
28. Fuchs T, Birbaumer N, Lutzenberger W et al. Neurofeedback treatment for attention-deficit/hyperactivity disorder in children: a comparison with methylphenidate. Appl Psychophysiol Biofeedback 2003; 28:1-12.
29. Heywood C, Beale I. EEG biofeedback vs. placebo treatment for attentiondeficit/hyperactivity disorder: a pilot study. J Atten Disord 2003; 7:43-55.
30. Drechsler R, Straub M, Doehnert M et al. 1Controlled evaluation of a neurofeedback training of slow cortical potentials in children with Attention Deficit/Hyperactivity Disorder (ADHD). Behav Brain Funct 2007;3.
31. Gevensleben H, Holl B, Albrecht B et al. Distinct EEG effects related to neurofeedback training in children with ADHD: a randomized controlled trial. Int J Psychophysiol 2009; 74:149-57.
32. Gevensleben H, Holl B, Albrecht B et al. Neurofeedback training in children with ADHD: 6-month follow-up of a randomised controlled trial. Eur Child Adolesc Psychiatry 2010; 19:715-24.
33. Arns M, Ridder Sd, Strehl U et al. Efficacy of neurofeedback treatment in ADHD: the effects on inattention, impulsivity and hyperactivity: a meta-analysis. Clin EEG Neurosci 2009; 40:180-9.
34. Pine D. Editorial: Evaluating new and old treatments for ADHD. J Child Psychol Psychiatry 2009; 50:767-8.
35. Kose S, Semerci B. Neurofeedback Therapy in Psychiatric Disorders. Bull Clin Psychopharmacol 2010; 20:193-5.
36. Klaassen C. Heavy Metals and Heavy-Metal Antagonists. In: Brunton L, Lazo J, Parker K, editors. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 11th edition ed. New York: McGraw-Hill; 2006. p. 1753-75.
37. Kala S, Jadhav A. Region-specific alterations in dopamine and serotonin metabolism in brains of rats exposed to low levels of lead. Neurotoxicology 1995; 16:297-308.
38. Wang H, Chen X, Yang B et al. Case-Control Study of Blood Lead Levels and Attention Deficit Hyperactivity Disorder in Chinese Children. Environ Health Perspect 2008; 116:1401-6.
39. Ha M, Kwon H, Lim M et al. Low blood levels of lead and mercury and symptoms of attention deficit hyperactivity in children: a report of the children's health and environment research (CHEER). Neurotoxicology 2009; 30:31-6.
40. Nicolescu R, Petcu C, Cordeanu A et al. Environmental exposure to lead, but not other neurotoxic metals, relates to core elements of ADHD in Romanian children: Performance and questionnaire data. Environ Res 2010; 110:476-83.
41. Cheuk D, Wong V. Attention-Deficit Hyperactivity Disorder and Blood Mercury Level: a Case-Control Study in Chinese Children. Neuropediatrics 2006; 37:234-40.
42. Chiang W. Mercury. In: Ford M, Delaney K, Ling L, Erickson T, editors. Clinical Toxicology. Philadelphia: WB Saunders; 2001. p. 737-43.
43. Stangle D, Smith D, Beaudin S et al. Succimer chelation improves learning, attention, and arousal regulation in lead-exposed rats but produces lasting cognitive impairment in the absence of lead exposure. Environ Health Perspect 2007; 115:201-9.
44. Van der Linde AA, Pillen S, Gerrits G et al. Stevens-Johnson syndrome in a child with chronic mercury exposure and 2,3-dimercaptopropane- 1-sulfonate (DMPS) therapy. Clin Toxicol (Phila) 2008; 46:479-81.
45. Baxter A, Krenzelok E. Pediatric fatality secondary to EDTA chelation. Clin Toxicol (Phila) 2008; 46:1083-4.
46. Wadman M. Autism study panned by critics. Nature 2008; 454:259.
47. Uzun G, Kardesoglu E, Uz O et al. Sudden death during hyperbaric oxygen therapy: Rare but it may occur. Undersea Hyperb Med 2010; 37:49-50.
48. Yildiz S, Aktas S, Cimsit M et al. Seizure incidence in 80,000 patient treatments with hyperbaric oxygen. Aviat Space Environ Med 2004;75:992-4.
49. Weaver L, Churchill S. Pulmonary edema associated with hyperbaric oxygen therapy. Chest 2001; 120:1407-9.
50. Stubberfield T, Parry T. Utilization of alternative therapies in attentiondeficit hyperactivity disorder. J Paediatr Child Health 1999; 35:450-3.
51. Transler C, Eilander A, Mitchell S et al. The Impact of Polyunsaturated Fatty Acids in Reducing Child Attention Deficit and Hyperactivity Disorders. J Atten Disord 2010 [Epub ahead of print].
52. Chen J, Hsu S, Hsu C et al. Dietary patterns and blood fatty acid composition in children with attention-deficit hyperactivity disorder in Taiwan. J Nutr Biochem 2004; 15:467-72.
53. Mitchell E, Aman M, Turbott S et al. Clinical characteristics and serum essential fatty acid levels in hyperactive children. Clin Pediatr (Phila) 1987; 26:406-11.
54. Colter A, Cutler C, Meckling K. Fatty acid status and behavioural symptoms of attention deficit hyperactivity disorder in adolescents: a casecontrol study. Nutr J 2008; 14:8.
55. Stevens L, Zentall S, Abate M et al. Omega-3 fatty acids in boys with behavior, learning, and health problems. Physiol Behav 1996;59:915-20.
56. Zimmer L, Vancassel S, Cantagrel S et al. The dopamine mesocorticolimbic pathway is affected by deficiency in n-3 polyunsaturated fatty acids. Am J Clin Nutr 2002; 75:662-7.
57. Swanson J, Kinsbourne M, Nigg J et al. Etiologic subtypes of attention- deficit/hyperactivity disorder: brain imaging, molecular genetic and environmental factors and the dopamine hypothesis. Neuropsychol Rev 2007; 17:39-59.
58. Aman M, Mitchell E, Turbott S. The effects of essential fatty acid supplementation by Efamol in hyperactive children. J Abnorm Child Psychol 1987; 15:75-90.
59. Arnold L, Kleykamp D, Votolato N et al. Gamma-linolenic acid for attention-deficit hyperactivity disorder: placebo-controlled comparison to D-amphetamine. Biol Psychiatry 1989; 25:222-8.
60. Voigt R, Llorente A, Jensen C et al. A randomized, double-blind, placebo-controlled trial of docosahexaenoic acid supplementation in children with attention-deficit/hyperactivity disorder. J Pediatr 2001; 139:189-96.
61. Hirayama S, Hamazaki T, Terasawa K. Effect of docosahexaenoic acid-containing food administration on symptoms of attentiondeficit/ hyperactivity disorder - a placebo-controlled double-blind study. Eur J Clin Nutr 2004; 58:467-73.
62. Stevens L, Zhang W, Peck L et al. EFA supplementation in children with inattention, hyperactivity, and other disruptive behaviors. Lipids 2003; 38:1007-21.
63. Sinn N, Bryan J. Effect of supplementation with polyunsaturated fatty acids and micronutrients on learning and behavior problems associated with child ADHD. J Dev Behav Pediatr 2007; 28:82-91.
64. Johnson M, Ostlund S, Fransson G et al. Omega-3/omega-6 fatty acids for attention deficit hyperactivity disorder: a randomized placebo-controlled trial in children and adolescents. J Atten Disord 2009; 12:394-401.
65. Gustafsson P, Birberg-Thornberg U, Duchén K et al. EPA supplementation improves teacher-rated behaviour and oppositional symptoms in children with ADHD. Acta Paediatr 2010:[Epub ahead of print].
66. Frederickson C, Suh S, Silva D et al. Importance of zinc in the central nervous system: the zinc-containing neuron. J Nutr 2000; 130(5S Suppl):1471-83.
67. Lepping P, Huber M. Role of zinc in the pathogenesis of attentiondeficit hyperactivity disorder: implications for research and treatment. CNS Drugs 2010; 24:721-8.
68. Bhatnagar S, Taneja S. Zinc and cognitive development. Br J Nutr 2001; 85(Suppl 2):139-45.
69. Arnold L, Votolato N, Kleykamp D et al. Does hair zinc predict amphetamine improvement of ADD/hyperactivity? Int J Neurosci 1990; 50:103-7.
70. Bekaroğlu M, Aslan Y, Gedik Y et al. Relationships between serum free fatty acids and zinc, and attention deficit hyperactivity disorder: a research note. J Child Psychol Psychiatry 1996; 37:225-7.
71. Yorbik O, Ozdag M, Olgun A et al. Prog Neuropsychopharmacol Biol Psychiatry. Potential effects of zinc on information processing in boys with attention deficit hyperactivity disorder 2008; 32:662-7.
72. Institute of Medicine Food and Nutrition Board. Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc. Washington, DC: National Academy Press; 2001.
73. Bilici M, Yildirim F, Kandil S et al. Double-blind, placebo-controlled study of zinc sulfate in the treatment of attention deficit hyperactivity disorder. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28:181-90.
74. Arnold L, DiSilvestro R. Zinc in attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2005; 15:619-27.
75. Akhondzadeh S, Mohammadi M, Khademi M. Zinc sulfate as an adjunct to methylphenidate for the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial [ISRCTN64132371]. BMC Psychiatry 2004;4.
76. Uçkardeş Y, Ozmert E, Unal F et al. Effects of zinc supplementation on parent and teacher behaviour rating scores in low socioeconomic level Turkish primary school children. Acta Paediatr 2009; 98:731-6.
77. Wigglesworth J, Baum H. Iron dependent enzymes in the brain. Yuodim M, editor. New York: Taylor and Francis; 1998.
78. Erikson K, Jones B, Hess E et al. Iron deficiency decreases dopamine D1 and D2 receptors in rat brain. Pharmacol Biochem Behav 2001; 69:409-18.
79. Konofal E, Lecendreux M, Arnulf I et al. Iron deficiency in children with attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med 2004; 158:1113-5.
80. Konofal E, Lecendreux M, Deron J et al. Effects of iron supplementation on attention deficit hyperactivity disorder in children. Pediatr Neurol 2008; 38:20-6.
81. Sever Y, Ashkenazi A, Tyano S et al. Iron treatment in children with attention deficit hyperactivity disorder. A preliminary report. Neuropsychobiology 1997; 35:178-80.
82. Westfall T, Westfall D. Neurotransmission. In: Brunton L, Lazo J, Parker K, editors. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 11th ed. New York: McGraw Hill; 2006. p. 137-81.
83. Sanders-Bush E, Mayer S. 5-Hydroxytryptamine (Serotonin): Receptor Agonists and Antagonists. In: Brunton L, Lazo J, Parker K, editors. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 11th ed. New York: McGraw Hill; 2006. p. 297-315.
84. Shaywitz B, Siegel N, Pearson H. Megavitamins for minimal brain dysfunction. A potentially dangerous therapy. JAMA 1977; 238:1749-50.
85. Haslam R, Dalby J, Rademaker A. Effects of megavitamin therapy on children with attention deficit disorders. Pediatrics 1984; 74:103-11.
86. Arnold L, Christopher J, Huestis R et al. Megavitamins for minimal brain dysfunction. A placebo-controlled study. JAMA 1978; 240:2642-3.
87. Kozielec T, Starobrat-Hermelin B. Assessment of magnesium levels in children with attention deficit hyperactivity disorder (ADHD). Magnes Res 1997; 10:143-8.
88. Mousain-Bosc M, Roche M, Polge A et al. Improvement of neurobehavioral disorders in children supplemented with magnesium-vitamin B6. I. Attention deficit hyperactivity disorders. Magnes Res 2006; 19:46-52.
89. Krummel D, Seligson F, Guthrie H. Hyperactivity: is candy causal? Crit Rev Food Sci Nutr 1996; 36:31-47.
90. Arnold L. Treatment alternatives for Attention-Deficit Hyperactivity Disorder (ADHD). J Atten Dis 1999; 3:30-48.
91. Carter C, Urbanowicz M, Hemsley R et al. Effects of a few food diet in attention deficit disorder. Arch Dis Child 1993; 69:564-8.

APA	KILINÇASLAN A, TUTKUNKARDAŞ M, MUKADDES N (2011). Complementary and alternative treatments of attention deficit hyperactivity disorder. , 94 - 102.
Chicago	KILINÇASLAN Ayşe,TUTKUNKARDAŞ Mustafa Deniz,MUKADDES Nahit Motavallı Complementary and alternative treatments of attention deficit hyperactivity disorder. (2011): 94 - 102.
MLA	KILINÇASLAN Ayşe,TUTKUNKARDAŞ Mustafa Deniz,MUKADDES Nahit Motavallı Complementary and alternative treatments of attention deficit hyperactivity disorder. , 2011, ss.94 - 102.
AMA	KILINÇASLAN A,TUTKUNKARDAŞ M,MUKADDES N Complementary and alternative treatments of attention deficit hyperactivity disorder. . 2011; 94 - 102.
Vancouver	KILINÇASLAN A,TUTKUNKARDAŞ M,MUKADDES N Complementary and alternative treatments of attention deficit hyperactivity disorder. . 2011; 94 - 102.
IEEE	KILINÇASLAN A,TUTKUNKARDAŞ M,MUKADDES N "Complementary and alternative treatments of attention deficit hyperactivity disorder." , ss.94 - 102, 2011.
ISNAD	KILINÇASLAN, Ayşe vd. "Complementary and alternative treatments of attention deficit hyperactivity disorder". (2011), 94-102.

APA	KILINÇASLAN A, TUTKUNKARDAŞ M, MUKADDES N (2011). Complementary and alternative treatments of attention deficit hyperactivity disorder. Nöropsikiyatri Arşivi, 48(2), 94 - 102.
Chicago	KILINÇASLAN Ayşe,TUTKUNKARDAŞ Mustafa Deniz,MUKADDES Nahit Motavallı Complementary and alternative treatments of attention deficit hyperactivity disorder. Nöropsikiyatri Arşivi 48, no.2 (2011): 94 - 102.
MLA	KILINÇASLAN Ayşe,TUTKUNKARDAŞ Mustafa Deniz,MUKADDES Nahit Motavallı Complementary and alternative treatments of attention deficit hyperactivity disorder. Nöropsikiyatri Arşivi, vol.48, no.2, 2011, ss.94 - 102.
AMA	KILINÇASLAN A,TUTKUNKARDAŞ M,MUKADDES N Complementary and alternative treatments of attention deficit hyperactivity disorder. Nöropsikiyatri Arşivi. 2011; 48(2): 94 - 102.
Vancouver	KILINÇASLAN A,TUTKUNKARDAŞ M,MUKADDES N Complementary and alternative treatments of attention deficit hyperactivity disorder. Nöropsikiyatri Arşivi. 2011; 48(2): 94 - 102.
IEEE	KILINÇASLAN A,TUTKUNKARDAŞ M,MUKADDES N "Complementary and alternative treatments of attention deficit hyperactivity disorder." Nöropsikiyatri Arşivi, 48, ss.94 - 102, 2011.
ISNAD	KILINÇASLAN, Ayşe vd. "Complementary and alternative treatments of attention deficit hyperactivity disorder". Nöropsikiyatri Arşivi 48/2 (2011), 94-102.